Bio-Rad Shares Sink 10.5 Percent After Bank Downgrades Stock on Lackluster Earnings Report | GenomeWeb

NEW YORK, Feb. 18 (GenomeWeb News) - Shares in Bio-Rad were down 10.48 percent, or $6.07, at $51.83 in late-afternon trading after lackluster fourth-quarter earnings caused an investment bank to downgrade the stock today.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.